The Weekly Litigation News Digest is now live. Subscribe now

IP Verse

Cross Reactive Siglec Antibodies - EP3191517

The patent EP3191517 was granted to Innate Pharma on Nov 4, 2020. The application was originally filed on Sep 9, 2015 under application number EP15762562A. The patent is currently recorded with a legal status of "Revoked".

EP3191517

INNATE PHARMA
Application Number
EP15762562A
Filing Date
Sep 9, 2015
Status
Revoked
Jun 16, 2023
Publication Date
Nov 4, 2020
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

GRAF VON STOSCHAug 3, 2021-ADMISSIBLE

Patent Citations (1) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
OPPOSITIONWO2016038064

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents